Stockreport

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [TheStreet.com]

TuHURA Biosciences, Inc.  (HURA) 
PDF TAMPA, Fla. April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therape [Read more]